Bisoprolol Fumarate And Hydrochlorothiazide Tablet, Film Coated
Product Images NDC 71335-1769

6 FDA label images from Bryant Ranch Prepack · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Bisoprolol Fumarate And Hydrochlorothiazide (NDC 71335-1769). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Biso Api Structure (Api Pic New1)

Biso Api Structure (Api Pic New1)
Chemical structure of Bisoprolol Fumarate, depicting the molecular arrangement of bisoprolol with fumarate salt. The structure includes aromatic ring and functional groups characteristic of the compound.*
FDA Label Image

Hctz Api Structure (Api Pic New2)

Hctz Api Structure (Api Pic New2)
Chemical structure of Bisoprolol Fumarate and Hydrochlorothiazide showing a chlorinated benzene ring with sulfonamide and amino substituents, representing key functional groups of the active ingredients.*
FDA Label Image

Label (Lbl713351769)

Label (Lbl713351769)
Packaging label for Bisoprolol Fumarate and Hydrochlorothiazide 5 mg/6.25 mg film coated tablets by Bryant Ranch Prepack. The label includes storage instructions at room temperature (20°-25°C), a note to keep drugs out of reach of children, and a bar code. It compares to Ziac 5/6.25 mg Tablet from Edenbridge Pharmaceuticals LLC and indicates a 30 count package.*
FDA Label Image

Table 1 (Table 1 New)

Table 1 (Table 1 New)
Data table comparing sitting systolic/diastolic blood pressure and heart rate changes after 3-4 weeks in two studies with Bisoprolol Fumarate and Hydrochlorothiazide. It shows mean decreases and drug effects versus placebo for different dosages.*
FDA Label Image

Table-3 (Table 3 New)

Table-3 (Table 3 New)
A table presenting the percentage of patients experiencing various adverse experiences in a clinical study. It compares all adverse experiences and drug-related adverse experiences between placebo and Bisoprolol Fumarate and Hydrochlorothiazide 5/6.25 mg combination groups, categorized by body system such as cardiovascular, respiratory, central nervous system, musculoskeletal, psychiatric, and gastrointestinal.*
FDA Label Image

Table-2 (Table New 2)

Table-2 (Table New 2)
A data table titled 'Serum Potassium Data from U.S. Placebo Controlled Studies' showing potassium levels and hypokalemia rates for different groups, including Placebo and various doses of a product labeled B2.5, B5, B10, and D 25 mg. The table presents mean change in potassium (mEq/L) and percentage of hypokalemia among subjects.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.